Manufacturing

TriPharm Services announces creation of pharmaceutical manufacturing center

TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment.

Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts

Thermo Fisher Scientific has launched a new handheld X-ray fluorescence analyser called IonicX XRF Analyzer to help pharmaceutical and biopharmaceutical manufacturers to verify the identity of ionic salts in warehouses within seconds.

Pfizer to invest £411m in new US gene therapy manufacturing facility

Pfizer is set to invest an additional $500m (£411m) to build an advanced gene therapy manufacturing facility in Sanford, North Carolina, US.

Kite to bolster cell therapy manufacturing capabilities with new viral vector facility

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.

Nexus Pharmaceuticals to build sterile injectable production facility in Wisconsin

US-based healthcare firm Nexus Pharmaceuticals is set to construct a new sterile injectable manufacturing facility in Wisconsin, US.

BMS plans to sell Celgene’s psoriasis drug Otezla

Bristol-Myers Squibb (BMS) is planning to divest Celgene’s psoriasis drug Otezla (apremilast), in a bid to expedite the process of merger with Celgene.

Gamida Cell, Lonza establish commercial manufacturing agreement for omidubicel

Gamida Cell and Lonza announced that the companies have entered into a strategic manufacturing agreement.

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.

Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon

Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices.